Monopar Therapeutics Inc. MNPR
Set alert
70.32 USD -1.59 -2.21%
At close · Oct 30
70.32 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
69.35 Day range 72.76
50.07 52-week range 124.82
- YTD
- +7.69%
- 1 year
- -17.92%
- Open
- 71.36
- Prev close
- 71.91
- Mkt cap
- 472.00M
- Vol
- 197.76K
- Avg vol
- 171.66K
- EPS
- -2.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 69.35
- High
- 72.76
- Forward P/E
- -10.17
- Beta
- 1.10
- Short ratio
- 0.15
- Inst. own
- 24.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 17.85
- 200-d avg
- 7.12
- 1y target
- 27.33
5Y chart
Events in this range
- May 15, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Jun 1, 2023Rating: HC Wainwright & Co. · — → Buy
- Mar 28, 2024Earnings: —; estimate -0.85; surprise —%
- Apr 11, 2024Rating: JonesTrading · Hold → Buy
- May 9, 2024Earnings: —; estimate -0.85; surprise —%
- May 9, 2024Earnings: -0.5; estimate -0.85; surprise 41.18%
- May 10, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 9, 2024Earnings: -0.5; estimate -0.45; surprise -11.11%
- Aug 9, 2024Earnings: —; estimate -0.45; surprise —%
- Aug 13, 2024Split: 1 for 5
- Aug 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 8, 2024Earnings: -0.37; estimate -0.46; surprise 19.57%
- Nov 11, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (83)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| RSI: Overbought | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| MACD: Buy Signal | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| RSI: Overbought | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| RSI: Overbought | Oct 21, 2024 | 2 years ago |
| RSI: Overbought | Sep 23, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| SMA: Bullish | Apr 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| RSI: Overbought | Feb 19, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| RSI: Oversold | Nov 6, 2023 | 2 years ago |
| RSI: Oversold | Oct 2, 2023 | 3 years ago |
| RSI: Oversold | Aug 14, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| RSI: Oversold | Apr 24, 2023 | 3 years ago |
| SMA: Bearish | Mar 27, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| RSI: Overbought | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Oct 10, 2022 | 4 years ago |
| RSI: Oversold | Sep 5, 2022 | 4 years ago |
| RSI: Oversold | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | Jun 20, 2022 | 4 years ago |
| RSI: Oversold | Jun 20, 2022 | 4 years ago |
| SMA: Bullish | Jun 6, 2022 | 4 years ago |
| SMA: Bearish | Mar 7, 2022 | 4 years ago |
| SMA: Bullish | Feb 21, 2022 | 4 years ago |
Key statistics
- Market cap
- 126.67M
- Enterprise value
- 48.26M
- Trailing P/E
- 0.00
- Forward P/E
- -10.17
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.80
- EPS (TTM)
- -1.98
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.43M
- Total cash
- 7.12M
- Total debt
- 0
- Return on equity
- -102.31%
- Shares outstanding
- 5.28M
- Short % of float
- 10.22%
- 50-day average
- 17.85
- 200-day average
- 7.12
Analyst view
Consensus: none
Price target (mean) 27.33 -61.1% downside
Now 70.32
- Target (low)
- 22.00
- Target (mean)
- 27.33
- Target (high)
- 37.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.42.
Financials — quick view
MNPR Revenue — quarterly 0
MNPR Net income — quarterly -5.31M
MNPR EPS — quarterly -0.62
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.46 | -0.37 | +0.09 | +19.57% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | -0.50 | -0.05 | -11.11% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | -0.50 | +0.35 | +41.18% |
| Mar 28, 2024 | Dec 1, 2023 | -0.85 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2024 | JonesTrading | up | Hold | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 15, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- monopartx.com
News
- Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
- Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
- Monopar Appoints Jeffrey D. Kent, M.D.
- Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
- This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
- Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
- Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
- Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
- BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
- Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Your note
Sign in to keep a note on MNPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON RAYMOND WILLIAM | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 26,863 |
| BROWN MICHAEL J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 4,513,800 |
| CITTADINE ANDREW | Chief Operating Officer | Conversion of Exercise of derivative security | Jun 27, 2024 | 193,065 |
| KLAUSNER ARTHUR J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 3,086,260 |
| LEO KARL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 17, 2019 | 0 |
| MAZAR ANDREW PAUL | Officer and Director | Conversion of Exercise of derivative security | Mar 30, 2022 | 4,300,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.27% | 14,066 | 337.58K | Sep 29, 2024 |
| Wells Fargo & Company | 0.01% | 500 | 12.00K | Sep 29, 2024 |
| NewEdge Advisors, LLC | 0.01% | 600 | 14.40K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 512 | 12.29K | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 16 | 384 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 13 | 312 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.17% | 9,034 | 216.82K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 9,024 | 216.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 5,241 | 125.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 2,621 | 62.90K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 2,690 | 64.56K | Oct 30, 2024 |